CGON
What one share of CG Oncology holds
Biological Products, (No Diagnostic Substances)
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec (cretostimogene), an investigational oncolytic immunotherapy with a dual mechanism of action designed both to eliminate cancer cells directly by selective replication and indirectly by activating an anti-tumor immune response, as a potential backbone therapy in a broad range of patients afflicted with bladder cancer.
CG Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.08 |
|---|---|
| Profit | −$2.72 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.18 |
| Cash and investments | $11.64 |
| Debt | $0.03 |
| Book value | $11.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.05 | −$15.65 | — | −$10.55 | — | −$23.57 |
| 2024 | $0.02 | −$1.41 | $0.00 | −$1.26 | — | $9.63 |
| 2025 | $0.05 | −$2.08 | $0.00 | −$1.71 | — | $9.33 |